Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Sestak

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2018
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5Mitch Dowsett, Ivana Sestak, Meredith M Regan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trialAlistair Ring, Ivana Sestak, Michael Baum, et al.
Breast (Edinburgh, Scotland)|August 8, 2016
IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancerRoopa Lakhanpal, Ivana Sestak, Bruce Shadbolt, et al.
Journal of the National Cancer Institute|July 13, 2016
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine TherapyRichard Buus, Ivana Sestak, Ralf Kronenwett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2015
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast CancerMitch Dowsett, Ivana Sestak, Richard Buus, et al.
Arhiv Za Higijenu Rada I Toksikologiju|November 16, 2012
Sulphur cycling between terrestrial agroecosystem and atmosphereZeljka Zgorelec, Gordana Pehnec, Ferdo Bašić, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Molecular Drivers of Onco<i>type</i> DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC StudyRichard Buus, Ivana Sestak, Ralf Kronenwett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapyMitch Dowsett, Ivana Sestak, Elena Lopez-Knowles, et al.
Cancers|July 2, 2021
A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer RiskDebora Macis, Valentina Aristarco, Harriet Johansson, et al.
Preventive Medicine Reports|February 20, 2024
Body composition changes during breast cancer preventive treatment with anastrozole: Findings from the IBIS-II trialMary Pegington, Hui Zhen Tam, Adam Brentnall, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2018
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5Mitch Dowsett, Ivana Sestak, Meredith M Regan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trialAlistair Ring, Ivana Sestak, Michael Baum, et al.
Breast (Edinburgh, Scotland)|August 8, 2016
IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancerRoopa Lakhanpal, Ivana Sestak, Bruce Shadbolt, et al.
Journal of the National Cancer Institute|July 13, 2016
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine TherapyRichard Buus, Ivana Sestak, Ralf Kronenwett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2015
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast CancerMitch Dowsett, Ivana Sestak, Richard Buus, et al.
Arhiv Za Higijenu Rada I Toksikologiju|November 16, 2012
Sulphur cycling between terrestrial agroecosystem and atmosphereZeljka Zgorelec, Gordana Pehnec, Ferdo Bašić, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Molecular Drivers of Onco<i>type</i> DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC StudyRichard Buus, Ivana Sestak, Ralf Kronenwett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapyMitch Dowsett, Ivana Sestak, Elena Lopez-Knowles, et al.
Cancers|July 2, 2021
A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer RiskDebora Macis, Valentina Aristarco, Harriet Johansson, et al.
Preventive Medicine Reports|February 20, 2024
Body composition changes during breast cancer preventive treatment with anastrozole: Findings from the IBIS-II trialMary Pegington, Hui Zhen Tam, Adam Brentnall, et al.
Pageof 7